Critical Therapeutics : Phase II Clinical Trial for Zileuton Injection

Jun 02, 2008 - Critical Therapeutics, Inc. (Nasdaq: CRTX) announced top-line results from its Phase II clinical trial of the injectable formulation of zileuton (zileuton injection), the Company's investigational compound for acute asthma in the emergency department (ED). The clinical trial was designed to explore the pulmonary function profile, safety, tolerability and pharmacokinetic profile of zileuton injection.
Asthma results in approximately two million ED visits and 500,000 hospitalizations each year in the U.S., according to the Allergy and Asthma Foundation of America. It is estimated that ED visits and hospitalizations for asthma account for more than 50 percent of the healthcare costs of the disease... Critical Therapeutics' Press Release -

Critical Therapeutics : Definitive Agreement to Merge with Cornerstone BioPharma

May 01, 2008 - Critical Therapeutics, Inc. (NASDAQ: CRTX) and Cornerstone BioPharma Holdings, Inc., a privately-held company, announced the signing of a definitive merger agreement.
Cornerstone is a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders... Critical Therapeutics' Press Release - Cornerstone BioPharma's Press Release -

Critical Therapeutics : Phase I Clinical Trial of the R(+) Isomer of Zileuton

April 8, 2008- Critical Therapeutics, Inc. (Nasdaq: CRTX) announced the results of its Phase I clinical trial to assess the safety and tolerability of an oral single dose of the R(+) isomer of zileuton in healthy subjects. R(+) zileuton combined in equal proportion with its mirror image isomer, S(-) zileuton, comprise racemic zileuton, which is the pharmaceutical ingredient in ZYFLO CR(TM) (zileuton) extended-release tablets... Critical Therapeutics' Press Release -

Critical Therapeutics, Phase III Trial of Zileuton in Patients with Acute Exacerbations of COPD

Oct. 15, 2007- Critical Therapeutics (Nasdaq: CRTX) announced the start of patient enrollment in the LEUKO study, a randomized, double-blind, placebo-controlled efficacy trial to examine the effects of ZYFLO(R) (zileuton tablets) used in the treatment of adults with Chronic Obstructive Pulmonary Disease (COPD). The purpose of this trial is to examine the effectiveness of ZYFLO at reducing the length of a hospital stay for adults who are hospitalized for a COPD exacerbation, or a worsening of their COPD symptoms... Critical Therapeutics' Press Release-

Critical Therapeutics, Phase I Clinical Trial of the R(+) Isomer of Zileuton

October 1, 2007 - Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced the initiation of a Phase I clinical trial to assess the safety and tolerability of an oral single dose of the R(+) isomer of zileuton in healthy subjects. R(+) zileuton combined in equal proportion with its mirror image isomer, S(-) zileuton, comprise racemic zileuton, which is the pharmaceutical ingredient in ZYFLO® (zileuton tablets) and ZYFLO CR(TM) (zileuton) extended-release tablets...In addition to asthma, the successful development of the R(+) isomer may also allow for possible development opportunities in other diseases - such as Chronic Obstructive Pulmonary Disease.. Critical Therapeutics' Press Release -